Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Postoperative MMC‐EMDA induction vs MMC‐PD induction therapy

Serious adverse events

It is very uncertain whether postoperative MMC‐EMDA induction changes serious adverse events compared with MMC‐PD induction therapy (very low certainty).

1 finding from 1 review

Intravesical electromotive drug administration for non‐muscle invasive bladder cancer 2017 · Cochrane Headline outcomes only
RR 1.5 [0.27, 8.45]
1 study · 72 participants
Very low

Postoperative MMC‐EMDA induction vs postoperative BCG induction therapy

Serious adverse events

It is very uncertain whether postoperative MMC‐EMDA induction changes serious adverse events compared with postoperative BCG induction therapy (very low certainty).

1 finding from 1 review

Intravesical electromotive drug administration for non‐muscle invasive bladder cancer 2017 · Cochrane Headline outcomes only
RR 0.75 [0.18, 3.11]
1 study · 72 participants
Very low

Postoperative MMC‐EMDA with sequential BCG induction and maintenance vs postoperative BCG induction and maintenance therapy

Serious adverse events

It is very uncertain whether postoperative MMC‐EMDA with sequential BCG induction and maintenance changes serious adverse events compared with postoperative BCG induction and maintenance therapy (very low certainty).

1 finding from 1 review

Intravesical electromotive drug administration for non‐muscle invasive bladder cancer 2017 · Cochrane Headline outcomes only
RR 1.02 [0.21, 4.94]
1 study · 212 participants
Very low